The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study
Open accessAbstract
In recent years the use of immunomodulating therapy to treat various cancers has been on the rise. Three checkpoint inhibitors have been approved by the Food and Drug Administration (ipilimumab, pembrolizumab and nivolumab). The use of these drugs comes with serious adverse events related to excessive immune activation, collectively known as immune-related adverse events (irAEs). We conducted a system-based review of 139 case reports/case series that have described these adverse events between January 2016 and April 2018, found in the PubMed database. There was a broad spectrum of presentations, doses and checkpoint inhibitors used. The most common check point inhibitor observed in our literature review was nivolumab. The most common adverse effects encountered were colitis (14/139), hepatitis (11/139), adrenocorticotropic hormone insufficiency (12/139), hypothyroidism (7/139), type 1 diabetes (22/139), acute kidney injury (16/139) and myocarditis (10/139). The treatment most commonly consisted of cessation of the immune checkpoint inhibitor, initiation of steroids and supportive therapy. This approach provided a complete resolution in a majority of cases; however, there were many that developed long-term adverse events with deaths reported in a few cases. The endocrine system was the mostly commonly affected with the development of type 1 diabetes mellitus or diabetic ketoacidosis being the most frequently reported adverse events. While immunomodulating therapy is a significant advance in the management of various malignancies, it is capable of serious adverse effects. Because the majority of the cases developed pancreatic dysfunction within five cycles of therapy, in addition to the evaluation of other systems, pancreatic function should be closely monitored to minimize adverse impact on patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“overactivation of the immune system to boost antitumor immunity can act as a double-edged sword, leading to the development of irAEs that can range from mild rash to severe colitis to life-threatening myocarditis (114, 115).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“30-60% of patients experience irAEs of any grade”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Experimental — accuracy not yet measuredIn the citing paper
“approximately 10-20% experience more severe grade 3 or 4 irAEs”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
In the citing paper
“Newly developed autoimmune disease, such as type I diabetes in patients with no prior history of the disease, following checkpoint therapy has also been reported to occur”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 2×
“This over-activation can potentially affect multiple organ systems including the gastrointestinal tract, kidneys, nervous system, liver, eyes, skin, pancreas and endocrine system [8-12].”
BackgroundThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 4×
“This over-activation can potentially affect multiple organ systems including the gastrointestinal tract, kidneys, nervous system, liver, eyes, skin, pancreas and endocrine system [8-12].”
BackgroundInfluentialFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 4×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundInfluentialThe Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814 · cited 1×
“This process is regulated by stimulatory, co-stimulatory, and inhibitory (checkpoint) signals [4-6].”
BackgroundBertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · cited 1×
“Many of the conditions can be life-threatening calling for discontinuation of treatment, long-term corticosteroids and at times anti-tumor necrosis factor therapy [13].”
BackgroundOkazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689 · cited 1×
“Another study published in Nature Medicine reported that mice deficient in the PD-1 immuno-inhibitory co-receptor develop autoimmune dilated cardiomyopathy with production of high titer autoantibodies against a heart specific protein [115].”
BackgroundImmune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515 · cited 4×
“The patients who received FDA-approved checkpoint inhibitors such as ipilimumab, pembrolizumab and nivolumab were considered whether they received the treatment in a clinical trial or as part of standard of care.”
BackgroundInfluentialCardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511 · cited 3×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundAbdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160221 · Cited by 444 · cited 1×
“The immune system has the inherent ability to distinguish self from non-self and can typically mount an attack on the non-self tissue such as cancer cells [1, 2].”
Shirali, A. C., Perazella, M. A., & Gettinger, S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.02.057 · Cited by 284 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
BackgroundPD-1 deficiency results in the development of fatal myocarditis in MRL mice
Wang, J., Okazaki, I.-M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 270 · cited 2×
“In this study a biopsy of the myocardium was performed which showed diffuse infiltration of CD4+ and CD8+ T cells and myeloid cells and there was a high titer of auto-antibodies against cardiac myosin [116].”
MethodResultVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundSmoldering myocarditis following immune checkpoint blockade
Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0296-4 · Cited by 201 · cited 3×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundLucas, J. A., Menke, J., Rabacal, W. A., Schoen, F. J., Sharpe, A. H., & Kelley, V. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2513 · Cited by 189 · cited 2×
“Journal of Immunotherapy reported a case of smoldering myocarditis [114].”
BackgroundInhibitory receptors as targets for cancer immunotherapy
Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 175 · cited 10×
“Thus far, there have been three immunotherapy drugs that have been approved by the Food and Drug Administration (FDA) [9, 10].”
BackgroundMethodInfluentialKawakami, H., Tanizaki, J., Tanaka, K., Haratani, K., Hayashi, H., Takeda, M., Kamata, K., Takenaka, M., Kimura, M., Chikugo, T., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0453-0 · Cited by 173 · cited 2×
“[44-46] Cholangitis 5 64 - 82 (75) Nivolumab-5 4 - 12 (8) Methylprednisolone/UDCA/ stent/prednisone, improved”
BackgroundFulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy
Okamoto, M., Okamoto, M., Gotoh, K., Masaki, T., Ozeki, Y., Ando, H., Anai, M., Sato, A., Yoshida, Y., Ueda, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12531 · Cited by 155 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Godwin, J. L., Jaggi, S., Sirisena, I., Sharda, P., Rao, A. D., Mehra, R., & Veloski, C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0245-2 · Cited by 140 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
Gardner, D. H., Jeffery, L. E., & Sansom, D. M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12834 · Cited by 139 · cited 1×
“In addition, there are multiple immunomodulators that target T-cell activation [7].”
BackgroundGauci, M.-L., Laly, P., Vidal-Trécan, T., Baroudjian, B., Gottlieb, J., Madjlessi-Ezra, N., Meda, L. D., Madelaine, I., Bagot, M., Basset‐Séguin, N., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2033-8 · Cited by 137 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Mechanisms of PDL1-mediated regulation of autoimmune diabetes
Guleria, I., Bupp, M. G., Dada, S., Fife, B. T., Tang, Q., Ansari, M. J., Trikudanathan, S., Vadivel, N., Fiorina, P., Yagita∥, H., et al. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.05.013 · Cited by 134 · cited 1×
“This process is regulated by stimulatory, co-stimulatory, and inhibitory (checkpoint) signals [4-6].”
BackgroundBehling, J., Kaes, J., Münzel, T. F., Grabbe, S., & Loquai, C. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000314 · Cited by 132 · cited 1×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundDoherty, G. J., Duckworth, A., Davies, S. E., Mells, G. F., Brais, R. J., Harden, S., Parkinson, C., & Corrie, P. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000268 · Cited by 123 · cited 3×
“[35-42] Hepatitis 11 42 - 80 (61) Pembrolizumab-5, nivolumab-6 1 - 17 (5) Methylprednisolone/corticosteroids/ prednisone/UDCA/mycophenolate, improved”
BackgroundChae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1913-7 · Cited by 121 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Chan, M. M. K., Kefford, R. F., Carlino, M. S., Clements, A., & Manolios, N. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000060 · Cited by 119 · cited 3×
“Immune checkpoints are inhibitory pathways that keep the immune system in check in order to maintain selftolerance and prevent autoimmunity [3, 8].”
BackgroundNivolumab-induced hypophysitis in a patient with advanced malignant melanoma
Okano, Y., Satoh, T., Horiguchi, K., Toyoda, M., Osaki, A., Matsumoto, S., Tomaru, T., Nakajima, Y., Ishii, S., Ozawa, A., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0161 · Cited by 117 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Hyponatraemia secondary to nivolumab-induced primary adrenal failure
Trainer, H., Hulse, P., Higham, C. E., Trainer, P., & Lorigan, P. (2016) · Endocrinology, Diabetes & Metabolism Case Reports · doi:10.1530/edm-16-0108 · Cited by 117 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Murakami, N., Borges, T. J., Yamashita, M., & Riella, L. V. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw024 · Cited by 116 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
Lowe, J. R., Perry, D. J., Salama, A. K. S., Mathews, C. E., Moss, L. G., & Hanks, B. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0196-z · Cited by 110 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Acute interstitial nephritis related to immune checkpoint inhibitors
Bellière, J., Meyer, N., Mazières, J., Ollier, S., Boulinguez, S., Delas, A., Ribes, D., & Faguer, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.358 · Cited by 105 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
BackgroundNivolumab-associated acute glomerulonephritis: a case report and literature review
Jung, K., Zeng, X., & Bilušić, M. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0408-2 · Cited by 102 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
BackgroundPolyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma
Paepegaey, A.-C., Lheure, C., Ratour, C., Lethielleux, G., Clerc, J., Bertherat, J., Kramkimel, N., & Groussin, L. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00170 · Cited by 102 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury
Gelsomino, F., Vitale, G., D’Errico, A., Bertuzzi, C. A., Andreoné, P., & Ardizzoni, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw649 · Cited by 101 · cited 2×
“[44-46] Cholangitis 5 64 - 82 (75) Nivolumab-5 4 - 12 (8) Methylprednisolone/UDCA/ stent/prednisone, improved”
BackgroundSemper, H., Muehlberg, F. L., Schulz‐Menger, J., Allewelt, M., & Grohé, C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.025 · Cited by 100
Aleksova, J., Lau, P. K. H., Soldatos, G., & McArthur, G. A. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-217454 · Cited by 98 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Love, V. A., Grabie, N., Duramad, P., Stavrakis, G., Sharpe, A. H., & Lichtman, A. H. (2007) · Circulation Research · doi:10.1161/circresaha.106.147124 · Cited by 97 · cited 1×
“CTLA-4 ablation also enhances cardio-pathogenicity reported in study published in circulation research with research showing that PD-1, PD-L1 and CTLA-4 play a role in preventing autoimmune myocarditis [117].”
ResultHansen, E., Sahasrabudhe, D. M., & Sievert, L. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1835-4 · Cited by 93 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
Miyoshi, Y., Ogawa, O., & Oyama, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.155 · Cited by 93 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Anti-PD1-induced collagenous colitis in a melanoma patient
Baroudjian, B., Lourenço, N., Pagès, C., Chami, I., Maillet, M., Bertheau, P., Bagot, M., Gornet, J., Lebbé, C., & Allez, M. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000252 · Cited by 91 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundSarocchi, M., Grossi, F., Arboscello, E., Bellodi, A., Genova, C., Bello, M. G. D., Rijavec, E., Barletta, G., Rossi, G., Biello, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0452 · Cited by 91 · cited 1×
“Troponin was studied as a biomarker of cardiac damage to predict myocarditis yet the efficacy of troponin is not yet proven [118].”
BackgroundNephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases
Kitchlu, A., Fingrut, W. B., Ávila-Casado, C., Chan, C. T., Crump, M., Hogg, D., & Reich, H. N. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.04.026 · Cited by 90 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
BackgroundLankes, K., Hundorfean, G., Harrer, T., Pommer, A. J., Agaimy, A., Angelovska, I., Tajmir-Riahi, A., Göhl, J., Schuler, G., Neurath, M. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1128611 · Cited by 88 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundMcMillen, B., Dhillon, M. S., & Yong-Yow, S. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-214603 · Cited by 87 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Primer on tumor immunology and cancer immunotherapy
Harris, T. J., & Drake, C. G. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-12 · Cited by 86 · cited 1×
“This process is regulated by stimulatory, co-stimulatory, and inhibitory (checkpoint) signals [4-6].”
BackgroundAcute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism
Win, M. A., Thein, K. Z., Qdaisat, A. Z., & Yeung, S. J. (2017) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2017.02.048 · Cited by 86 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Severe Esophagitis and Gastritis from Nivolumab Therapy
Boike, J. R., & DeJulio, T. J. (2017) · ACG Case Reports Journal · doi:10.14309/crj.2017.57 · Cited by 84 · cited 2×
“[31] Esophagitis and gastritis 1 93 Nivolumab 6 mo.”
BackgroundMunakata, W., Ohashi, K., Yamauchi, N., & Tobinai, K. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2101-4 · Cited by 81 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Friedman, C. F., Clark, V. R., Raikhel, A. V., Barz, T., Shoushtari, A. N., Momtaz, P., Callahan, M. K., Wolchok, J. D., Chapman, P. B., Hellmann, M. D., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw260 · Cited by 79 · cited 2×
“[48-52] Pancreatitis 6 43 - 76 (57) Pembrolizumab-2, nivolumab-4 2 - 19 (7) Prednisone/duodenal stent/ pancreaticoduodectomy/pancreatic enzymes/dexamethasone, improved”
BackgroundFatal Myocarditis Following Treatment with the PD ‐1 Inhibitor Nivolumab
Matson, D. R., Accola, M. A., Rehrauer, W. M., & Corliss, R. F. (2017) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13633 · Cited by 77 · cited 1×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundFaghfuri, E., Faramarzi, M. A., Nikfar, S., & Abdollahi, M. R. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1074862 · Cited by 76 · cited 2×
“The immune system has the inherent ability to distinguish self from non-self and can typically mount an attack on the non-self tissue such as cancer cells [1, 2].”
BackgroundKashima, J., Okuma, Y., Shimizuguchi, R., & Chiba, K. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2062-3 · Cited by 76 · cited 2×
“[47] Cholecystitis 1 63 Nivolumab 5 stent, ENBD, antibiotics, steroids”
BackgroundAcute hemorrhagic gastritis after nivolumab treatment
Kobayashi, M., Yamaguchi, O., Nagata, K., Nonaka, K., & Ryozawa, S. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.04.033 · Cited by 74 · cited 2×
“[32] Hemorrhagic gastritis 1 77 Nivolumab 10 Prednisolone, improved”
BackgroundUemura, M. I., Trinh, V. A., Haymaker, C., Jackson, N. A., Kim, D. W., Allison, J. P., Sharma, P., Vence, L. M., Bernatchez, C., Hwu, P., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0309-7 · Cited by 69 · cited 2×
“There were 21 cases involving the luminal digestive tract, 13 involving the liver, six involving the biliary tract and six involving the pancreas (Table 1) [14-52].”
BackgroundIgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma
Kishi, S., Minato, M., Saijo, A., Murakami, N., Tamaki, M., Matsuura, M., Murakami, T., Nagai, K., Abe, H., Nishioka, Y., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9814-17 · Cited by 67 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
BackgroundBrand, F. Z. A., Suter, N., Adam, J., Faulques, B., Maietta, A., Soulières, D., & Blais, N. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0332-z · Cited by 64 · cited 2×
“[33] Oral mucositis, esophagitis 1 69 Pembrolizumab 14 Methylprednisolone, prednisone, improved”
BackgroundNivolumab-Induced Colitis Treated by Infliximab
Yanai, S., Nakamura, S., & Matsumoto, T. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.09.017 · Cited by 63 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundOwonikoko, T. K., Kumar, M., Yang, S., Kamphorst, A. O., Pillai, R. N., Akondy, R. S., Nautiyal, V., Chatwal, M. S., Book, W., Sahu, A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1918-2 · Cited by 63 · cited 1×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundIkeuchi, K., Okuma, Y., & Tabata, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.001 · Cited by 62 · cited 2×
“[48-52] Pancreatitis 6 43 - 76 (57) Pembrolizumab-2, nivolumab-4 2 - 19 (7) Prednisone/duodenal stent/ pancreaticoduodectomy/pancreatic enzymes/dexamethasone, improved”
BackgroundNivolumab induced myxedema crisis
Khan, U., Rizvi, H., Sano, D., Chiu, J., & Hadid, T. H. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0213-x · Cited by 61 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab
Kitajima, K., Ashida, K., Wada, N. A., Suetsugu, R., Takeichi, Y., Sakamoto, S., Uchi, H., Matsushima, T., Shiratsuchi, M., Ohnaka, K., et al. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx018 · Cited by 60 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Pericardial effusion with tamponade physiology induced by nivolumab
Nesfeder, J., Elsensohn, A. N., Thind, M., Lennon, J., & Domsky, S. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.023 · Cited by 54 · cited 1×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundGelsomino, F., Vitale, G., & Ardizzoni, A. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0484-6 · Cited by 52
Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.244.33 · Cited by 52 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
Escandon, J., Peacock, S., Trabolsi, A., Thomas, D. B., Layka, A., & Lutzky, J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0205-2 · Cited by 49 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
BackgroundImmune checkpoint combinations from mouse to man
Ai, M., & Curran, M. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1650-8 · Cited by 47 · cited 2×
“This over-activation can potentially affect multiple organ systems including the gastrointestinal tract, kidneys, nervous system, liver, eyes, skin, pancreas and endocrine system [8-12].”
BackgroundCase of type 1 diabetes associated with less‐dose nivolumab therapy in a melanoma patient
Teramoto, Y., Nakamura, Y., Asami, Y., Imamura, T., Takahira, S., Nemoto, M., Sakai, G., Shimada, A., Noda, M., & Yamamoto, A. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13486 · Cited by 47 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Shiba, M., Inaba, H., Ariyasu, H., Kawai, S., Inagaki, Y., Matsuno, S., Iwakura, H., Yamamoto, Y., Nishi, M., & Akamizu, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9518-17 · Cited by 47 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Zeng, M. F., Chen, L., Ye, H. Y., Gong, W., Zhou, L. N., Li, Y. M., & Zhao, X. (2017) · Medicine · doi:10.1097/md.0000000000008426 · Cited by 45
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Li, L., Masood, A., Bari, S., Yavuz, S., & Grosbach, A. (2017) · Case Reports in Oncology · doi:10.1159/000456540 · Cited by 44 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Spänkuch, I., Gassenmaier, M., Tampouri, I., Noor, S., Forschner, A., Garbe, C., & Amaral, T. M. S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.018 · Cited by 44 · cited 2×
“[35-42] Hepatitis 11 42 - 80 (61) Pembrolizumab-5, nivolumab-6 1 - 17 (5) Methylprednisolone/corticosteroids/ prednisone/UDCA/mycophenolate, improved”
BackgroundLupu, J., Pagès, C., Laly, P., Delyon, J., Laloi-Michelin, M., Petit, A., Basset‐Séguin, N., Oueslati, I., Zagdanski, A., Young, J., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000405 · Cited by 44 · cited 2×
“Central hypothyroidism due to damage to the adrenal gland and a resultant decrease in thyroid stimulating hormone (TSH) was found in two cases [62, 70].”
BackgroundOhara, N., Ohashi, K., Fujisaki, T., Oda, C., Ikeda, Y., Yoneoka, Y., Hashimoto, T., Hasegawa, G., Suzuki, K. T., & Takada, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9074-17 · Cited by 44
Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer
Wu, Z., Lai, L., Li, M., Zhang, L., & Zhang, W. (2017) · Medicine · doi:10.1097/md.0000000000009431 · Cited by 43
Immune-Mediated Thrombocytopenia and Hypothyroidism in a Lung Cancer Patient Treated with Nivolumab
Jotatsu, T., Oda, K., Yamaguchi, Y., Noguchi, S., Kawanami, T., Kido, T., Satoh, M., & Yatera, K. (2017) · Immunotherapy · doi:10.2217/imt-2017-0100 · Cited by 42
Nivolumab-Associated Colitis Mimicking Ulcerative Colitis
Kubo, K., Kato, M., & Mabe, K. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.03.026 · Cited by 41 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundPathological Characterization of Nivolumab-Related Liver Injury in a Patient with Glioblastoma
Simonelli, M., Tommaso, L. D., Baretti, M., & Santoro, A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0057 · Cited by 39
Case Report: Pembrolizumab-Induced Type 1 Diabetes in a Patient with Metastatic Cholangiocarcinoma
Smith-Cohn, M., Gill, D. M., Voorhies, B. N., Agarwal, N., & Garrido‐Laguna, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0042 · Cited by 37
Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?
Bertha, M., Bellaguara, E., Kuzel, T. M., & Hanauer, S. B. (2017) · ACG Case Reports Journal · doi:10.14309/crj.2017.112 · Cited by 37 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundIyoda, T., Kurita, N., Takada, A., Watanabe, H., & Ando, M. (2018) · American Journal of Case Reports · doi:10.12659/ajcr.908570 · Cited by 37 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundAcute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma
Bottlaender, L., Breton, A.-L., de Laforcade, L., Dijoud, F., Thomas, L., & Dalle, S. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0261-2 · Cited by 36 · cited 1×
“The detailed results are presented in Table 5 [106-113].”
BackgroundTakaya, K., Sonoda, M., Fuchigami, A., & Hiyoshi, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8548-16 · Cited by 36 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Yasuda, Y., Urata, Y., Tohnai, R., Ito, S., Kawa, Y., Kono, Y., Hattori, Y., Tsuda, M., Sakuma, T., Negoro, S., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9230-17 · Cited by 36 · cited 2×
“[28, 29] Intestinal perforation 2 73, 65 Nivolumab-2 3, 3 Surgical intervention, improved”
BackgroundNivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma
Matsubara, T., Nishida, T., Higaki, Y., Tomita, R., Shimakoshi, H., Shimoda, A., Osugi, N., Sugimoto, A., Takahashi, K., Nakamatsu, D., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9851-17 · Cited by 35
Kumagai, R., Muramatsu, A., Nakajima, R., Fujii, M., 戒能賢太, Katakura, Y., Okumura, N., Ohara, G., Kagohashi, K., Satoh, H., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12627 · Cited by 32 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Changizzadeh, P. N., Mukkamalla, S. K. R., & Armenio, V. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0303-9 · Cited by 31 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Ariyasu, H., Inaba, H., OTA, T., YAMAOKA, H., Furukawa, Y., Iwakura, H., Doi, N., Yamamoto, Y., & Akamizu, T. (2018) · In Vivo · doi:10.21873/invivo.11244 · Cited by 31 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
Ishiwata, T., Ebata, T., Iwasawa, S., Matsushima, J., Ota, S., Nakatani, Y., Tsushima, K., Tada, Y., Tatsumi, K., & Takiguchi, Y. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8271-16 · Cited by 30 · cited 1×
“There were a total of five cases found of immunomodulators adversely affecting the pulmonary system as shown in Table 4 [103, 104, 105].”
BackgroundZarogoulidis, P., Chinelis, P., Athanasiadou, A., Tsiouda, T., Trakada, G., Kallianos, A., Veletza, L., Hatzibougias, D. I., Mihalopoulou, E., Goupou, E., et al. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.07.004 · Cited by 29 · cited 2×
“[28, 29] Intestinal perforation 2 73, 65 Nivolumab-2 3, 3 Surgical intervention, improved”
BackgroundNew onset diabetes after nivolumab treatment
Capitão, R., Bello, C., Fonseca, R. C., & Saraiva, C. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-220999 · Cited by 29 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment
Humayun, M. A., & Poole, R. (2016) · HORMONES · doi:10.14310/horm.2002.1656 · Cited by 28 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Histopathology of pembrolizumab-induced hepatitis: a case report
Aivazian, K., Long, G. V., Sinclair, E. C., Kench, J. G., & McKenzie, C. A. (2017) · Pathology · doi:10.1016/j.pathol.2017.07.010 · Cited by 27 · cited 2×
“[35-42] Hepatitis 11 42 - 80 (61) Pembrolizumab-5, nivolumab-6 1 - 17 (5) Methylprednisolone/corticosteroids/ prednisone/UDCA/mycophenolate, improved”
BackgroundKastrisiou, M., Kostadima, F.-L., Kefas, A., Zarkavelis, G., Kapodistrias, N., Ntouvelis, E., Petrakis, D., Papadaki, A., Vassou, A., & Pentheroudakis, G. E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000217 · Cited by 26 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Leonardi, G. C., Oxnard, G. R., Haas, A. V., Lang, J. P., Williams, J. S., & Awad, M. M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000173 · Cited by 24 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Fragulidis, G. P., Pantiora, E. V., Michalaki, V., Kontis, E. A., Primetis, E. C., Vezakis, A. I., & Polydorou, A. A. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217738325 · Cited by 24
Seki, T., Yasuda, A., Oki, M., Kitajima, N., Takagi, A., Nakajima, N., Miyajima, A., & Fukagawa, M. (2017) · PubMed · Cited by 23
Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration
Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K., & Hata, H. (2017) · Case Reports in Oncology · doi:10.1159/000471480 · Cited by 22 · cited 2×
“[35-42] Hepatitis 11 42 - 80 (61) Pembrolizumab-5, nivolumab-6 1 - 17 (5) Methylprednisolone/corticosteroids/ prednisone/UDCA/mycophenolate, improved”
BackgroundFulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma
Takahashi, A., Tsutsumida, A., Namikawa, K., & Yamazaki, N. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000418 · Cited by 22 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Kumagai, T., Kimura, M., Inoue, T., Tamiya, M., Nishino, K., & Imamura, F. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12431 · Cited by 19 · cited 1×
“There were a total of five cases found of immunomodulators adversely affecting the pulmonary system as shown in Table 4 [103, 104, 105].”
BackgroundNivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung
Verma, I., Modi, A., Tripathi, H., & Agrawal, A. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-213692 · Cited by 18 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Rawson, R. V., Robbins, E., Kapoor, R., Scolyer, R. A., & Long, G. V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.042 · Cited by 16 · cited 2×
“[48-52] Pancreatitis 6 43 - 76 (57) Pembrolizumab-2, nivolumab-4 2 - 19 (7) Prednisone/duodenal stent/ pancreaticoduodectomy/pancreatic enzymes/dexamethasone, improved”
BackgroundIntestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report
Yasuda, K., Tanaka, T., Ishihara, S., Otani, K., Nishikawa, T., Kiyomatsu, T., Kawai, K., Hata, K., Nozawa, H., Masui, Y., et al. (2017) · Surgical Case Reports · doi:10.1186/s40792-017-0370-7 · Cited by 16 · cited 3×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundImmunotherapy-induced autoimmune hypophysitis
Valecha, G. K., Pant, M., Ibrahim, U., & Atallah, J. P. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217727142 · Cited by 16 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Furudate, S., Fujimura, T., Kambayashi, Y., Hidaka, T., Hashimoto, A., & Aiba, S. (2016) · Case Reports in Oncology · doi:10.1159/000450974 · Cited by 14 · cited 2×
“[35-42] Hepatitis 11 42 - 80 (61) Pembrolizumab-5, nivolumab-6 1 - 17 (5) Methylprednisolone/corticosteroids/ prednisone/UDCA/mycophenolate, improved”
BackgroundTakenaka, T., Yamazaki, K., Miura, N., Harada, N., & Takeo, S. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0481-9 · Cited by 14 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundFulminant type 1 diabetes mellitus associated with pembrolizumab
Mizab, C., Pérez, M. S., Rey, M. D. S., & García, M. H. (2017) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.01.005 · Cited by 14 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
Shaaban, H. S., Kuru, S., & Khan, N. H. (2017) · International Journal of Critical Illness and Injury Science · doi:10.4103/ijciis.ijciis_15_17 · Cited by 14 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Diarrhoea during checkpoint blockade, not always colitis
Koldenhof, J. J., & Suijkerbuijk, K. P. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.024 · Cited by 14 · cited 3×
“There was one case report of a patient who developed pancreatic exocrine insufficiency that required life-time pancreatic enzyme replacement therapy [51].”
BackgroundCheckpoint Inhibitor-Associated Hypophysitis
Chang, L., & Yialamas, M. A. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4135-6 · Cited by 13 · cited 2×
“Central hypothyroidism due to damage to the adrenal gland and a resultant decrease in thyroid stimulating hormone (TSH) was found in two cases [62, 70].”
BackgroundDiabetes fulminante secundaria a tratamiento con pembrolizumab
Mizab, C., Pérez, M. S., Rey, M. D. S., & García, M. H. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.01.005 · Cited by 12
A Case of Drug-Induced Severe Endocrinopathies
Villarreal, J., Townes, D. A., Vrablik, M. E., & Ro, K. A. (2018) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000173 · Cited by 12 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Infliximab for severe colitis associated with nivolumab followed by ipilimumab
Fukumoto, T., Fujiwara, S., Tajima, S., Tamesada, Y., Sakaguchi, M., Oka, M., & Nishigori, C. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.14034 · Cited by 11 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundOgawara, D., Soda, H., Ikehara, S., Sumiyoshi, M., Iwasaki, K., Okuno, D., Dohtsu, Y., Taniguchi, H., Harada, T., Fukuda, Y., et al. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12494 · Cited by 10 · cited 1×
“There were a total of five cases found of immunomodulators adversely affecting the pulmonary system as shown in Table 4 [103, 104, 105].”
BackgroundFujii, Y., Nishikawa, Y., Nomura, M., Miyamoto, S., Uneno, Y., Horimatsu, T., & Muto, M. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8910-17 · Cited by 10 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundMurakami, N., Borges, T. J., Yamashita, M., & Riella, L. V. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw058 · Cited by 8
Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?
Middlebrooks, E. H., Westbrook, B. C., & Conry, R. M. (2017) · Radiology Case Reports · doi:10.1016/j.radcr.2017.09.008 · Cited by 6 · cited 1×
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Amin, N. P., Agarwal, M., Zainib, M., & Simone, C. B. (2017) · Practical Radiation Oncology · doi:10.1016/j.prro.2017.11.013 · Cited by 6 · cited 2×
“[48-52] Pancreatitis 6 43 - 76 (57) Pembrolizumab-2, nivolumab-4 2 - 19 (7) Prednisone/duodenal stent/ pancreaticoduodectomy/pancreatic enzymes/dexamethasone, improved”
BackgroundA Case of Enteritis Induced by Nivolumab
Kobayashi, T., Takahashi, K., & Terai, S. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.03.005 · Cited by 6 · cited 3×
“The incidence of enterocolitis with PD-1 inhibitors can be as high as 30% [14].”
BackgroundPembrolizumab‐induced hepatitis: diagnosis and treatment
Forschner, A., Schraml, C., Pierchalla, K., Weide, B., Eigentler, T., Lauer, U. M., & Garbe, C. (2017) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13037 · Cited by 5 · cited 2×
“[35-42] Hepatitis 11 42 - 80 (61) Pembrolizumab-5, nivolumab-6 1 - 17 (5) Methylprednisolone/corticosteroids/ prednisone/UDCA/mycophenolate, improved”
BackgroundInflammatory Bowel Disease in an Elderly Woman After Nivolumab Administration
Abe, K., Nakamura, N., Isono, A., Toyota, H., Arai, H., & Saito, K. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.372 · Cited by 5 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
BackgroundSemper, H., Muehlberg, F. L., Schulz‐Menger, J., Allewelt, M., & Grohé, C. (2017) · Pneumologie · doi:10.1055/s-0037-1598454 · Cited by 4 · cited 1×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundUnusual case of immune-related colitis
Issa, M., & Milioglou, I. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221319 · Cited by 3 · cited 2×
“[14-27] Enterocolitis/ enteritis/colitis 14 32 - 85 (65) Pembrolizumab-3, nivolumab-11 1 - 19 (13) Prednisone/infliximab/mesalazine/ budesonide, improved”
Background
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
Teixeira, A. F., ten Dijke, P., & Zhu, H.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 211
D’Souza, M., Nielsen, D., Svane, I. M., Iversen, K., Rasmussen, P. V., Madelaire, C., Fosbøl, E., Køber, L., Gustafsson, F., Andersson, C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa884 · Cited by 171
Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer
Jin, X., Liu, Z., Yang, D., Yin, K., & Chang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948647 · Cited by 156
Metadata
- Authors
- Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., Levitt, M., Asif, A., & Hossain, M. A.
- Affiliations
- Jersey Shore University Medical Center (US)
- Corresponding author
- Gupta, Varsha
- Venue
- Journal of Clinical Medicine Research
- Publisher
- Elmer Press, Inc.
- Published
- 2019
- Volume
- 11
- Issue
- 4
- Pages
- 225-236
- ISSN
- 1918-3003 (ISSN-L)
- 1918-3011
- PMC
- PMC6436564
- OpenAlex
- W2921474571
- Cited by
- 179
- References
- 123
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 16 · 2023: 13 · 2022: 21 · 2021: 40 · 2020: 53 · 2019: 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Journal of Clinical Medicine Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, CTLA-4 inhibitors, nivolumab, pembrolizumab, ipilimumab, colitis, hepatitis, adrenal insufficiency, hypothyroidism, type 1 diabetes, diabetic ketoacidosis, acute kidney injury, myocarditis, pancreatic dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.